Article Details

BioXcel Therapeutics Announces First Patients Dosed in SERENITY III Phase 3 Trial for ...

Retrieved on: 2022-12-02 17:37:33

Tags for this article:

Click the tags to see associated articles and topics

BioXcel Therapeutics Announces First Patients Dosed in SERENITY III Phase 3 Trial for .... View article details on HISWAI: https://www.pharmiweb.com/press-release/2022-12-02-5/bioxcel-therapeutics-announces-first-patients-dosed-in-serenity-iii-phase-3-trial-for-acute-treatment-of-agitation-in-adults-with-bipolar-i-or-ii-disorder-or-schizophrenia

Excerpt

(Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and ...

Article found on: www.pharmiweb.com

View Original Article

This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up